JAMES WALKER & CO. LIMITED

Credit Opinion: CONDITIONAL

The company has a strong balance sheet with minimal leverage and substantial net assets, but recent financial performance has deteriorated sharply—sales fell 7% and the company swung from a £2.5M profit before tax to a £1.0M loss. The cash position is negligible (£57k), and liquidity is tight given the high working capital intensity (30.1% of revenue). The business is a wholly-owned subsidiary of James Walker Group Limited, which provides implicit group support, but the entity’s standalone earnings strain and operational risks (Keystone ERP implementation, PFAS exposure, tariff uncertainty) warrant close oversight. Approval should be conditional on financial covenants and regular monitoring.

Financial Strength

• Balance sheet: Net assets of £27.3M against total liabilities of just £4.5M—a very low debt burden. Shareholders’ funds have been stable over the last five years (range £24–28M), indicating no dividend leakage or material capital erosion.
• Leverage: Total liabilities to net assets ratio is 16.7% (2024: 18.1%), so the company is lightly geared. No bank borrowings or long-term debt are evident from the data.
• Earnings quality: The transition from profit to loss is concerning. The reported loss before tax of £970k was driven by increased cross-company charges (Keystone project), under-recovery of labour costs, and rising input costs. The operating margin went from +5.1% to –2.8% year-on-year.
• Reserves: P&L reserves (embedded in shareholders’ funds) are positive and have remained between £24M and £28M. No accumulated losses threaten the capital base.

Cash Flow Assessment

• Liquidity position: Cash at bank is only £57k (2024: £57k, 2023: £145k). This is very low relative to turnover of £41.7M. Given the scale, the company is likely operating within a group cash-pooling arrangement, so the low cash balance may be normal for a subsidiary.
• Working capital: Average working capital as a percentage of revenue increased from 26.4% to 30.1%, reflecting deliberate stock build to mitigate supply chain risks. This absorbs cash and will pressure liquidity if turnover continues to decline.
• Capital expenditure: £2.35M invested in FY2025 (down from £3.98M in FY2024). CapEx is funded internally, as there is no apparent external debt. However, given the loss-making position, the company will need to rely on operational improvement or group funding to meet ongoing investment needs.
• Debt service: No external debt is evident, so the immediate burden is minimal. Any new facility would be senior and likely secured, with strong asset cover given the £27.3M net asset base.

Monitoring Points

• Revenue trajectory: A further decline in sales could exacerbate margin pressure and working capital strain. Watch for signs of a turnaround in H1 2026.
• Profitability recovery: The company needs to return to positive operating margins. Monitor the under-recovery of labour costs and whether transfer price adjustments are implemented.
• Keystone project execution: The ERP go-live in the next 12 months carries material operational risk (supply disruption, cost overruns). A failed implementation could impair cash flow and customer relationships.
• PFAS exposure: Over 90% of elastomer compounds now have PFAS-free alternatives, but any outstanding regulatory action could affect a portion of the product range.
• Group support: As a 75%+ owned subsidiary, any change in group strategy (e.g., dividend demands, intercompany pricing) could directly impact cash flow. Request regular intercompany balance confirmations.
• Cash levels: Even with pooling, a sustained cash balance below £500k relative to turnover above £40M is a flag. Request management accounts showing true net cash from group perspective.